Delord, Jean-Pierre
Argilés, Guillem
Fayette, Jerôme
Wirth, Lori
Kasper, Stefan
Siena, Salvatore
Mesia, Ricard
Berardi, Rossana
Cervantes, Andrés
Dekervel, Jeroen
Zhao, Sylvia
Sun, Yongjian
Hao, Huai-Xiang
Tiedt, Ralph
Vicente, Sergio
Myers, Andrea
Siu, Lillian L.
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 7 February 2020
Accepted: 19 March 2020
First Online: 14 May 2020
Compliance with ethical standards
:
: JP. Delord reports research funding from F. Hoffmann-La Roche, Novartis Pharmaceuticals Corporation, Genentech, Bristol-Myers Squibb, Debiopharm, and Merck Sharpe & Dohme; advisory board participation for Bristol-Myers Squibb, Genentech, Novartis Pharmaceuticals Corporation, Merck Sharpe & Dohme and Takeda; patent holding in the field of molecular signature of cancer drugs effects. G. Argilés reports research funding, travel grants and advisory board participation for F. Hoffmann-La Roche, Bristol-Myers Squibb, Bayer, Servier, Amgen, Merck Serono and Menarini; honoraria to his institution from Bayer, Servier, Novartis Pharmaceuticals Corporation, Boehringer Ingelheim, Boston Pharmaceuticals, F. Hoffmann-La Roche, and Genentech. J. Fayette reports honoraria for consultancy or advisory role from AstraZeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, Merck Serono, Innate Pharma, and Biogen; research funding from AstraZeneca and Bristol-Myers Squibb; travel, accommodation, or expenses from Bristol-Myers Squibb, AstraZeneca and Merck Sharpe & Dohme. L. Wirth reports acting in an advisory role for Eisai, Loxo Oncology, Merck, Ayala, Cue Biopharma and Genentech. S. Kasper reports personal fees, research grants, and advisory board membership from Roche, Merck Serono, Lilly, Amgen, Servier, Sanofi Aventis, Bristol-Myers Squibb, and Merck Sharpe & Dohme. S. Siena reports acting in an advisory role for Amgen, Bayer, Bristol-Myers Squibb, Roche, Merck, Merck Sharpe & Dohme, Novartis Pharmaceuticals Corporation, and Sanofi. R. Mesia reports an advisory role for Merck, Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Roche, and Nanobiotix; speaker bureaus for Merck, Bristol-Myers Squibb, and Merck Sharpe & Dohme. A. Cervantes reports research grants to his institution form Novartis Pharmaceuticals Corporation to develop clinical trials on investigational compounds. J. Dekervel reports speaker fees, consulting fees or travel grants from Amgen, Bayer, Ipsen, Novartis Pharmaceuticals Corporation, Merck and Servier. L. Siu reports research funding for her institution from Novartis Pharmaceuticals Corporation for the conduct of this study. A. Myers, Y. Sun, H.-X. Hao, R. Tiedt, S. Vicente, and S. Zhao are all employed by Novartis Pharmaceuticals Corporation. R. Berardi declares that she has no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.